Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 1079 • 2015 ACR/ARHP Annual Meeting
The Potential Effect on Recruitment of Restricting Skin Scores Eligibility Criteria in Early Diffuse Scleroderma Trials
Robyn T. Domsic¹, Dinesh Khanna², Mary Lucas³, Virginia D. Steen⁴, Daniel E. Furst⁵, Robert Lafyatis⁶ and Thomas A. Medsger Jr.⁷, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Boston University School of Medicine, Boston, MA, ⁷Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: There is increasing interest in cohort enrichment for clinical trials of early diffuse SSc (dcSSc). Recent EUSTAR database analysis (Maurer et al. 2015)…
Abstract Number: 1175 • 2015 ACR/ARHP Annual Meeting
Blood Outgrowth Endothelial Cells Isolated from Systemic Sclerosis Patients Exhibit a Pro-Inflammatory Phenotype
Robert Good¹, Sarah L. Trinder², Christopher P. Denton³, David Abraham⁴ and Alan M. Holmes¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Vascular complications are a key pathological feature of systemic sclerosis (SSc) affecting the microcirculation and arterioles. Under normal circumstances the endothelium acts as a…
Abstract Number: 1872 • 2015 ACR/ARHP Annual Meeting
Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma
Julie J. Paik¹, Andrew Mammen², Fredrick M. Wigley³, Ami A. Shah⁴, Laura K. Hummers⁵ and Michael Polydefkis⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Neurology, Johns Hopkins University, Baltimore, MD
Title: Symptomatic and electrodiagnostic features of peripheral neuropathy in scleroderma Background/Purpose: Peripheral neuropathy in scleroderma has been poorly characterized and the prevalence is unknown. The…
Abstract Number: 1882 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis
Elana J. Bernstein¹, Veronica J. Berrocal², Virginia D. Steen³, Victoria K. Shanmugam^4,5, Ami A. Shah⁶, Monique E. Hinchcliff⁷, Faye N. Hant⁸, Jessica K. Gordon⁹, Tracy M. Frech¹⁰, Robyn T. Domsic¹¹, Shervin Assassi¹² and Dinesh Khanna¹³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Division of Rheumatology, The George Washington University, Washington, DC, ⁵Director, Division of Rheumatology, The George Washington University, Washington, DC, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Rheumatology, Northwestern University, Chicago, IL, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Patients with diffuse cutaneous systemic sclerosis (dcSSc) have…
Abstract Number: 1888 • 2015 ACR/ARHP Annual Meeting
There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach
Sindhu Johnson¹, Medha Soowamber², Jaap Fransen³, Dinesh Khanna⁴, Frank H.J. van den Hoogen⁵, Murray Baron⁶, Marco Matucci Cerinic⁷, Christopher P. Denton⁸, Thomas A. Medsger Jr.⁹, Patricia E. Carreira¹⁰, Gabriela Riemekasten¹¹, Jorg HW. Distler¹², Armando Gabrielli¹³, Virginia D. Steen¹⁴, Lorinda Chung¹⁵, Richard Silver¹⁶, John Varga¹⁷, Ulf Müller-Ladner¹⁸, Madelon C. Vonk¹⁹, Ulrich A. Walker²⁰, Frank Wollheim²¹, Ariane L. Herrick²², Daniel E. Furst²³, Lazlo Czirjak²⁴, Otylia Kowal-Bielecka²⁵, Francesco Del Galdo²⁶, Maurizio Cutolo²⁷, Nicolas Hunzelmann²⁸, Charles Murray²⁹, Ivan Foeldvari³⁰, Luc Mouthon³¹, Nemanja Damjanov³², Bashar Kahaleh³³, Tracy M. Frech³⁴, Shervin Assassi³⁵, Lesley Ann Saketkoo³⁶ and Janet E. Pope³⁷, ¹Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ²Rheumatology, University of Toronto/ Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁶Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, ⁷Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, ⁸Centre for Rheumatology, Royal Free Hospital, London, United Kingdom, ⁹Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, ¹⁰Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Rheumatology, Human medicine, BERLIN, Germany, ¹²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹³Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ¹⁴Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹⁶Div Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ¹⁷Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁸Rheumatology, Internal Medicine, Bad Nauheim, Germany, ¹⁹Rheumatology, Rheumatology, Nijmegen, Netherlands, ²⁰Rheumatology, Systemic Sclerosis, Basel, Switzerland, ²¹Rheumatology, Lund University Hospital, Lund, Sweden, ²²Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²⁴University of Pécs Medical Center, Pécs, Hungary, ²⁵Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ²⁶University of Leeds, Leeds, United Kingdom, ²⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²⁸Department of Dermatology, University of Cologne, Cologne, Germany, ²⁹Department of Gastroenterology, Royal Free Hospital, London, United Kingdom, ³⁰Rheumatology, Hamburg, Germany, ³¹Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ³²Resavska 69, Institute of Rheumatology, Belgrade, Serbia, ³³Medicine/Rheumatology, The University of Toledo, Toledo, OH, ³⁴Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, ³⁵Rheumatology, University of Texas Medical School at Houston, Houston, TX, ³⁶Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³⁷University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a family of diseases unified by the presence of immune activation, vasculopathy and fibrosis. The concept of SSc subsets cannot…
Abstract Number: 1889 • 2015 ACR/ARHP Annual Meeting
Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Natalie K. Kozij¹, John T. Granton², Philip E. Silkoff³, John Thenganatt⁴, Shobha Chakravorty⁴ and Sindhu R. Johnson⁵, ¹Department of Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Temple University, Philadelphia, PA, ⁴Respirology, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁵Toronto Scleroderma Program, Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institue of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: We evaluated the ability of alveolar and conducting airway nitric oxide (NO) to discriminate between systemic sclerosis (SSc) with and without lung involvement, idiopathic…
Abstract Number: 1901 • 2015 ACR/ARHP Annual Meeting
Association of Serum Adipokines Adipsin, Adiponectin, and Leptin/Adiponectin Ratio with Systemic Sclerosis
Benjamin Korman¹, Roberta Goncalves Marangoni¹, Monique E. Hinchcliff², Sanjiv Shah³, Mary A. Carns⁴, Rosalind Ramsey-Goldman⁵ and John Varga⁶, ¹Division of Rheumatology, Northwestern University, Chicago, IL, ²Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Chicago, IL, ⁴Rheumatology, Northwestern University, Chicago, IL, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
Background/Purpose: Patients with systemic sclerosis (SSc) display reductions in adipose tissue, particularly intradermal adipose tissue. There are currently no well-validated serum biomarkers in SSc, and…
Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma
Edward Stern^1,2, Cassandra Hong², Voon H. Ong², Aine Burns¹, Robert Unwin³ and Christopher P. Denton⁴, ¹Nephrology, Royal Free Hospital, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, UCL Division of Medicine, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…
Abstract Number: 765 • 2014 ACR/ARHP Annual Meeting
Gene-Gene Interaction of IRF5 and BLK Polymorphisms in US and Spanish Cohorts of Systemic Sclerosis (SSc)
Pravitt Gourh¹, Yoonhee Kim², Sandeep K. Agarwal³, Filemon K. Tan⁴, Shervin Assassi⁴, Javier Martin⁵, Frank C. Arnett⁴ and Maureen D Mayes⁴, ¹NIAMS-Rheumatology, National Institutes of Health, Bethesda, MD, ²NIH, Bethesda, MD, ³Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁵Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose Systemic sclerosis (SSc) is a complex autoimmune disease and several genetic loci increasing SSc susceptibility have been identified with small to modest effect sizes.…
Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Kristina E.N. Clark¹, Henry Lopez², Xu Shiwen¹, Bahja Ahmed Abdi¹, George Martin³, Korsa Khan⁴, David J. Abraham¹, Christopher P. Denton⁵ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Murigenics, Vallejo, CA, ³Aero Dap, Vallejo, CA, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…
Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Thomas Frauenfelder¹, Anna Winklehner¹, Thi Dan Linh Nguyen¹, Rucsandra Dobrota^2,3, Stephan Baumüller¹, Britta Maurer² and Oliver Distler², ¹Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…
Abstract Number: 2716 • 2014 ACR/ARHP Annual Meeting
Development of a “Renal Crisis Prevention Card” As an Educational Tool Aimed at Improving Outcomes in High-Risk Patients with Systemic Sclerosis
Lee S. Shapiro^1,2,3, Lesley Ann Saketkoo⁴, Jessica F. Farrell^2,3,5 and Kim Fligelstone⁶, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Center, Saratoga Springs, NY, ³The Center for Rheumatology, Albany, NY, ⁴Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁶Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a devastating complication of SSc. The introduction of effective treatment with ACE inhibition (ACE-I) in 1979 dramatically reduced…
Abstract Number: 2699 • 2014 ACR/ARHP Annual Meeting
Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts
Veronika K. Jaeger¹, Andrew Aubin², Nancy Baldwin³, Kim Fligelstone⁴, Robyn Sims⁵, Joep Welling⁶, Ryan Burrill⁷, Kerri Connolly⁷, Tracy Frech⁸, Jessica K. Gordon⁹, Tanaka Ngcozana¹⁰, Monika Kowalczyk¹¹, Matthew R. Lammi¹², Ulrich A. Walker¹ and Lesley Ann Saketkoo¹³, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ²Louisiana State University School of Medicine, New Orleans, LA, ³Scleroderma Foundation - Chicago Support Group, Chicago, IL, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Scleroderma Australia, Victoria, Australia, ⁶The Dutch Patient Organization for Systemic Autoimmune Diseases, Utrecht, Netherlands, ⁷Scleroderma Foundation, Boston, MA, ⁸Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, ¹¹DIvision of Gastroenterology, Tulane University School of Medicine, New Orleans, LA, ¹²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ¹³Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: SSc is a complex, diffuse, devastating health condition of vascular injury, inflammation and fibrosis resulting in multiple organ-system derangements with high impact on…
Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Aryeh Fischer³, Jerry A. Molitor⁴ and Virginia D. Steen⁵, ¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ³Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…
Abstract Number: 1930 • 2014 ACR/ARHP Annual Meeting
The Value of Repeated Nailfold Capillaroscopy in Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands
B. de Boer¹, J. Meijs¹, J. van Aken², T.W.J. Huizinga¹, A.a. Schouffoer³ and J.K. de Vries-Bouwstra⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Spaarne Ziekenhuis, Hoofddorp, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Nailfold capillaroscopy is an important tool to differentiate primary Raynaud's phenomenon (PRP) from secondary Raynaud's phenomenon (SRP). Based on possible transition from PRP to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.